# FDA 483 - Charu Aggarwal, MD, MPH, Hematology-Oncology Division - March 28, 2017

Source: https://www.globalkeysolutions.net/records/483/charu-aggarwal-md-mph-hematology-oncology-division/d67ab368-a7a4-4177-b7bf-d00b89e6180f

> FDA 483 for Charu Aggarwal, MD, MPH, Hematology-Oncology Division on March 28, 2017. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Charu Aggarwal, MD, MPH, Hematology-Oncology Division
- Inspection Date: 2017-03-28
- Product Type: drugs
- Office Name: Philadelphia District Office
- Summary: An FDA inspection of Charu Aggarwal, MD, MPH, Hematology-Oncology Division in Philadelphia, PA, revealed significant deficiencies in the conduct of a clinical investigation. The principal investigator and staff failed to adhere to the study protocol, lacked adequate oversight, and maintained inadequate and inaccurate case histories. These issues indicate serious non-compliance with clinical trial regulations.

## Related Documents

- [EIR - 2017-03-28](https://www.globalkeysolutions.net/records/eir/charu-aggarwal-md-mph-hematology-oncology-division/f802efbe-43f6-4614-a142-2ac0a6b40622)

## Related Officers

- [investigator](https://www.globalkeysolutions.net/people/marcelo-o-mangalindan-jr/9fe13d26-0c5e-4559-be36-812970fa67ce)

Company: https://www.globalkeysolutions.net/companies/charu-aggarwal-md-mph-hematology-oncology-division/8e6529bd-6bbe-400c-a06b-816a5ff26a98

Office: https://www.globalkeysolutions.net/offices/philadelphia-district-office/c5ec7398-b3d5-4125-9793-fb7b972578d8